Adrestia Therapeutics is a technology company.
Adrestia Therapeutics has raised $230.0M across 1 funding round.
Adrestia Therapeutics has raised $230.0M in total across 1 funding round.
Adrestia Therapeutics is a biotechnology company developing first-in-class therapies for genetic diseases, particularly neurologic, neuromuscular, and cardiomyopathic disorders, using a proprietary synthetic rescue platform to identify novel drug targets.[1][2] The platform decodes genetic networks by systematically mining the human genome for functionally connected genes that can correct the effects of causative mutations, which are often undruggable directly, enabling oligonucleotide or oral small molecule treatments.[2][5] Based at Babraham Research Campus in Cambridge, England, Adrestia advances an in-house pipeline complemented by alliances like target discovery with GSK and a Huntington’s disease collaboration with University College London researchers.[1][2]
The company serves patients with serious and rare genetic disorders, solving the challenge of targeting non-druggable mutations through broader genetic rescue strategies.[1][2] Early momentum includes a Series A financing round co-led by Ahren Innovation Capital and GSK, positioning Adrestia to build a synthetic rescue 'Atlas' of the human genome.[2]
Adrestia Therapeutics was co-founded by Professor Steve Jackson, a pioneer in synthetic lethality who co-originated olaparib—the first drug approved for cancers from inherited mutations—and the deep technology investment fund Ahren Innovation Capital, which co-led the Series A alongside GSK.[2] The idea emerged from Jackson's foundational work in synthetic rescue, extended by collaborations like The Jackson Laboratory's genomic analyses and screening, to create therapies that repair cellular balance in genetic diseases.[2]
Pivotal early moments include establishing alliances with GSK for multi-target discovery and with Dr. Sarah Tabrizi at University College London for Huntington’s disease, building on decades of research to launch the company's platform and pipeline.[2]
Adrestia rides the wave of precision medicine and gene therapy expansion, where advances in genomics enable functional rather than direct mutation targeting amid rising demand for rare disease treatments.[1][2] Timing aligns with maturing tools like CRISPR and AI-driven genetics, amplified by regulatory incentives for orphan drugs and investor interest in synthetic biology platforms.[2]
Market forces favoring Adrestia include a surge in undruggable target solutions—90% of disease genes remain challenging—and partnerships with pharma giants like GSK, accelerating validation.[2][5] The company influences the ecosystem by pioneering synthetic rescue, potentially expanding the druggable genome and inspiring similar approaches in biotech, much like synthetic lethality transformed oncology.[2]
Adrestia is poised to advance its pipeline toward clinical proof-of-concept, with near-term milestones in Huntington’s and in-house programs leveraging the synthetic rescue Atlas for multiple indications.[2] Trends like AI-genomics integration and oligonucleotide scalability will shape progress, potentially yielding first approvals in rare neurologic diseases within 5-7 years. Influence may evolve through expanded alliances and spinouts, solidifying its role as a genetic rescue leader—echoing its origins in olaparib's breakthrough against inherited mutations.[2]
Adrestia Therapeutics has raised $230.0M in total across 1 funding round.
Adrestia Therapeutics's investors include 7percent Ventures, Ahren Innovation Capital.
Adrestia Therapeutics has raised $230.0M across 1 funding round. Most recently, it raised $230.0M Series A in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $230.0M Series A | 7percent Ventures, Ahren Innovation Capital |